Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study.
Sagar Lonial(Emory University), Monique C. Minnema(University Medical Center Utrecht), Thierry Façon(Université de Lille), Marek Hus(Medical University of Lublin), Natalie S. Callander(University of Wisconsin–Madison), Paul G. Richardson(Harvard University), L. Mary Smith, Vincent Ribrag(Institut Gustave Roussy), Sebastian Grosicki(Medical University of Silesia), Therese Collingwood(Providence College), Vladimir Vorobyev(Botkin Hospital), Beata Holkova(Virginia Commonwealth University), Hang Quach(The University of Melbourne), Jing Yu(Providence College), Kevin Song(Vancouver General Hospital), Chang Ki Min(The Catholic University of Korea Seoul St. Mary's Hospital), Ira Gupta(Io Therapeutics (United States)), Brandon E. Kremer(Providence College), Shinta Cheng, Katarina Uttervall(Karolinska University Hospital)
Cited by 25
Related Papers
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k